Daiichi Sankyo Begins Patient Dosing In Tropion Breast02 Phase 3 Trial Of Datopotamab Deruxtecan In Patients With Previously Untreated Metastatic Tnbc

Daiichi Sankyo Announced That The First Patient Was Dosed In The Global Tropion-Breast02 Phase 3 Trial Evaluating The Efficacy And Safety Of Datopotamab Deruxtecan (Dato-Dxd) Versus Investigator